Skamene Tanya, Crump Michael, Savage Kerry J, Reiman Tony, Kuruvilla John, Good David, LeBrun David, Meyer Ralph M, Sehn Laurie H, Soulières Denis, Stakiw Julie, Laferriere Nicole, Luminari Stefano, Shepherd Lois E, Djurfeldt Marina, Zhu Liting, Chen Bingshu E, Hay Annette E
a Canadian Cancer Trials Group, Queen's University , Kingston , Canada.
b Princess Margaret Cancer Centre , Toronto , Canada.
Leuk Lymphoma. 2017 Oct;58(10):2319-2327. doi: 10.1080/10428194.2017.1312379. Epub 2017 May 15.
Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous malignancy. Of the 619 patients with relapsed and refractory (R/R) aggressive lymphoma enrolled in the Canadian Cancer Trials Group LY.12 phase 3 trial, 59 (9.5%) had PTCL. Among these, 81% had advanced stage disease, 41% had an International Prognostic Score ≥3, and 41% were refractory to primary therapy. Within the PTCL cohort, the overall response rate after two cycles of salvage chemotherapy was 36%; no difference was observed between dexamethasone, cytarabine, cisplatin (10/30, 33%), and gemcitabine, cisplatin, dexamethasone (11/29, 38%) therapy. At one year, event-free survival (EFS) was 16% and overall survival (OS) was 28%. For PTCL patients, who received autologous stem cell transplant, two-year EFS and OS were 21% and 42%, respectively. Patients with PTCL had inferior OS (HR 0.49, p < .0001) and EFS (HR 0.53, p < .0001) compared to B-cell lymphoma. Outcomes for patients with R/R PTCL are poor with currently available therapies.
外周T细胞淋巴瘤（PTCL）是一种罕见的异质性恶性肿瘤。在加拿大癌症试验组LY.12 3期试验纳入的619例复发难治性（R/R）侵袭性淋巴瘤患者中，59例（9.5%）患有PTCL。其中，81%为晚期疾病，41%的国际预后评分≥3，41%对初始治疗难治。在PTCL队列中，挽救性化疗两个周期后的总缓解率为36%；地塞米松、阿糖胞苷、顺铂（10/30，33%）与吉西他滨、顺铂、地塞米松（11/29，38%）治疗之间未观察到差异。一年时，无事件生存期（EFS）为16%，总生存期（OS）为28%。接受自体干细胞移植的PTCL患者，两年EFS和OS分别为21%和42%。与B细胞淋巴瘤相比，PTCL患者的OS（风险比0.49，p＜0.0001）和EFS（风险比0.53，p＜0.0001）较差。目前可用的治疗方法治疗R/R PTCL患者的预后较差。
